


# BLEPHAMIDE®

(sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile

## DESCRIPTION


BLEPHAMIDE® (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) is a sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid which have the following chemical structures:



Sulfacetamide sodium

MW = 254.24

$C_8H_9N_2NaO_3S \cdot H_2O$



Prednisolone acetate

MW = 402.49

$C_{23}H_{30}O_6$

**Chemical Names:** Sulfacetamide sodium: N-sulfanilylacетamide monosodium salt monohydrate. Prednisolone acetate: 11 $\beta$ ,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate.

Each mL of BLEPHAMIDE® contains: **Actives:** sulfacetamide sodium 10% and prednisolone acetate 0.2%; **Inactives:** phenylmercuric acetate 0.0008%; mineral oil; petrolatum and lanolin alcohol; and white petrolatum.

## CLINICAL PHARMACOLOGY

Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antibacterial drug may be used when this inhibition is considered to be clinically significant in a particular case.

When a decision to administer both a corticosteroid and an antibacterial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained.

The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

## Microbiology

Sulfacetamide exerts a bacteriostatic effect against susceptible bacteria by restricting the synthesis of folic acid

required for growth through competition with p-aminobenzoic acid.

Some strains of these bacteria may be resistant to sulfacetamide or resistant strains may emerge *in vivo*.

The anti-infective component in **BLEPHAMIDE**<sup>®</sup> ointment is included to provide action against specific organisms susceptible to it. Sulfacetamide sodium is active *in vitro* against susceptible strains of the following microorganisms: *Escherichia coli*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus (viridans group)*, *Haemophilus influenzae*, *Klebsiella* species, and *Enterobacter* species. This product does not provide adequate coverage against: *Neisseria* species, *Pseudomonas* species, and *Serratia marcescens* (see [INDICATIONS AND USAGE](#)).

## INDICATIONS AND USAGE

**BLEPHAMIDE**<sup>®</sup> ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitis is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: *Escherichia coli*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus (viridans group)*, *Haemophilus influenzae*, *Klebsiella* species, and *Enterobacter* species.

The product does not provide adequate coverage against: *Neisseria* species, *Pseudomonas* species, and *Serratia marcescens*.

A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

## CONTRAINDICATIONS

**BLEPHAMIDE**<sup>®</sup> ophthalmic ointment is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

**BLEPHAMIDE**<sup>®</sup> ophthalmic ointment is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides and to other corticosteroids (see [WARNINGS](#)). (Hypersensitivity to the antimicrobial component occurs at a higher rate than for other components.)

## WARNINGS

NOT FOR INJECTION INTO THE EYE.

Prolonged use of corticosteroids may result in posterior subcapsular cataract formation and may increase intraocular pressure in susceptible individuals, resulting in ocular hypertension/glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.

If the product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it

may be difficult in children and uncooperative patients. Corticosteroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical corticosteroids.

In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection.

The use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of corticosteroid medication in the treatment of herpes simplex requires great caution.

Prolonged use of **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment may suppress the host response and thus increase the hazard of secondary ocular infections.

Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi.

A significant percentage of staphylococcal isolates are completely resistant to sulfonamides.

Acute anterior uveitis may occur in susceptible individuals, primarily Blacks.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered, irrespective of the route of administration.

If signs of hypersensitivity, skin rash, or other serious reaction occur, discontinue use of this preparation. Cross-sensitivity among corticosteroids has been demonstrated (see [ADVERSE REACTIONS](#)). **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment contains the preservative phenylmercuric acetate, which may cause allergic-type reactions in susceptible patients.

## **PRECAUTIONS**

### **General**

The initial prescription and renewal of the medication order beyond 8 g of ointment should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, the patient should be re-evaluated.

The possibility of fungal infections of the cornea should be considered after prolonged corticosteroid dosing. Fungal cultures should be taken when appropriate.

Use with caution in patients with severe dry eye.

The p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.

Ophthalmic ointments may retard corneal healing.

### **Information for Patients**

If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician (see [WARNINGS](#)).

This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the

tube tip to eyelids or to any other surface. The use of this tube by more than one person may spread infection. Keep tube tightly closed when not in use. Keep out of the reach of children.

## Laboratory Tests

Eyelid cultures and tests to determine the susceptibility of organisms to sulfacetamide may be indicated if signs and symptoms persist or recur in spite of the recommended course of treatment with **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment.

## Drug Interactions

**BLEPHAMIDE**<sup>®</sup> ophthalmic ointment is incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.

## Carcinogenesis, Mutagenesis, Impairment of Fertility

Prednisolone has been reported to be noncarcinogenic. Long-term animal studies for carcinogenic potential have not been performed with sulfacetamide.

One author detected chromosomal nondisjunction in the yeast *Saccharomyces cerevisiae* following application of sulfacetamide sodium. The significance of this finding to topical ophthalmic use of sulfacetamide sodium in the human is unknown.

Mutagenic studies with prednisolone have been negative. Studies on reproduction and fertility have not been performed with sulfacetamide. A long-term chronic toxicity study in dogs showed that high oral doses of prednisolone prevented estrus. A decrease in fertility was seen in male and female rats that were mated following oral dosing with another glucocorticosteroid.

## Pregnancy

### Teratogenic Effects

Animal reproduction studies have not been conducted with sulfacetamide sodium. Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate well-controlled studies in pregnant women dosed with corticosteroids.

Kernicterus may be precipitated in infants by sulfonamides being given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.

**BLEPHAMIDE**<sup>®</sup> ophthalmic ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

## Nursing Mothers

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.

Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for serious adverse reactions in nursing infants from sulfacetamide sodium and prednisolone acetate ophthalmic ointments, a decision should be made whether to discontinue nursing or to discontinue the medication.

## **Pediatric Use**

Safety and effectiveness in children below the age of 6 years have not been established.

## **ADVERSE REACTIONS**

The following adverse reactions have been identified during use of **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions have occurred with corticosteroid/antibacterial combination drugs which can be attributed to the corticosteroid component, the antibacterial component, or the combination.

Reactions occurring with **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment include: cataract, dizziness, eye discharge, eyelid edema, eyelid erythema, eye irritation, eye pain, eye pruritus, and hypersensitivity including rash, skin pruritus, urticaria, ocular hyperemia, and visual disturbance (blurry vision).

Reactions occurring most often from the presence of the antibacterial ingredient are allergic sensitizations. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see [WARNINGS](#)).

The reactions due to the corticosteroid component in decreasing order of frequency are: delayed wound healing, elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage, and posterior subcapsular cataract formation.

Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticism after use of topical corticosteroids.

Corticosteroid-containing preparations can also cause acute anterior uveitis or perforation of the globe. Mydriasis, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids.

## **Secondary Infection**

The development of secondary infection has occurred after use of combinations containing corticosteroids and antibacterials. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of corticosteroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used.

Secondary bacterial ocular infection following suppression of host responses also occurs.

## **DOSAGE AND ADMINISTRATION**

A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.

Not more than 8 g should be prescribed initially.

The dosing of **BLEPHAMIDE**<sup>®</sup> ophthalmic ointment may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.

If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see [PRECAUTIONS](#)).

## **HOW SUPPLIED**

**BLEPHAMIDE®** (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% is supplied sterile in ointment tubes of the following size:

3.5 g - NDC 0023-0313-04

**Storage:**

Store at 15°-25°C (59°-77°F).

**Revised: 06/2018**

Distributed by: Allergan USA, Inc.  
Madison, NJ 07940

© 2018 Allergan. All rights reserved.  
All trademarks are the property of their respective owners.

**PRINCIPAL DISPLAY PANEL**

NDC 0023-0313-04

3.5 g

**BLEPHAMIDE®**

(sulfacetamide

sodium and

prednisolone

acetate


ophthalmic

ointment, USP)

10%/0.2%

sterile

Rx Only



# BLEPHAMIDE

sulfacetamide sodium and prednisolone acetate ointment

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0023-0313
Route of Administration	OPHTHALMIC		

**Active Ingredient/Active Moiety**

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5)	SULFACETAMIDE SODIUM	100 mg in 1 g
PREDNISOLONE ACETATE (UNII: 8B2807733D) (PREDNISOLONE - UNII:9PHQ9Y1OLM)	PREDNISOLONE ACETATE	2 mg in 1 g

**Inactive Ingredients**

<b>Ingredient Name</b>	<b>Strength</b>
PHENYLMERCURIC ACETATE (UNII: OSX88361UX)	
MINERAL OIL (UNII: T5L8T28FGP)	
PETROLATUM (UNII: 4T6H12BN9U)	
LANOLIN ALCOHOLS (UNII: 884C3FA9HE)	

**Packaging**

<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:0023-0313-04	1 in 1 CARTON	01/01/1987	
1		3.5 g in 1 TUBE; Type 0: Not a Combination Product		

**Marketing Information**

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
ANDA	ANDA087748	01/01/1987	

**Labeler - Allergan, Inc. (144796497)****Establishment**

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Allergan Sales, LLC		362898611	MANUFACTURE(0023-0313)

Revised: 6/2018

Allergan, Inc.